Cover Image
市場調查報告書

TAR DNA結合蛋白43 (TDP-43):開發中產品分析

TAR DNA-Binding Protein 43 (TDP-43) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 365787
出版日期 內容資訊 英文 46 Pages
訂單完成後即時交付
價格
Back to Top
TAR DNA結合蛋白43 (TDP-43):開發中產品分析 TAR DNA-Binding Protein 43 (TDP-43) - Pipeline Review, H1 2016
出版日期: 2016年06月30日 內容資訊: 英文 46 Pages
簡介

本報告提供以TAR DNA結合蛋白43 (TDP-43)為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,加上企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

TAR DNA結合蛋白43 (TDP-43) 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Biogen, Inc.
  • ImStar Therapeutics Inc.
  • Primary Peptides, Inc.
  • SK Biopharmaceuticals Co., Ltd.
  • TauRx Therapeutics Ltd.

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0261TDB

Summary

Global Markets Direct's, 'TAR DNA-Binding Protein 43 (TDP-43) - Pipeline Review, H1 2016', provides in depth analysis on TAR DNA-Binding Protein 43 (TDP-43) targeted pipeline therapeutics.

The report provides comprehensive information on the TAR DNA-Binding Protein 43 (TDP-43), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in TAR DNA-Binding Protein 43 (TDP-43) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for TAR DNA-Binding Protein 43 (TDP-43)
  • The report reviews TAR DNA-Binding Protein 43 (TDP-43) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in TAR DNA-Binding Protein 43 (TDP-43) targeted therapeutics and enlists all their major and minor projects
  • The report assesses TAR DNA-Binding Protein 43 (TDP-43) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to TAR DNA-Binding Protein 43 (TDP-43) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for TAR DNA-Binding Protein 43 (TDP-43)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding TAR DNA-Binding Protein 43 (TDP-43) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • TAR DNA-Binding Protein 43 (TDP-43) Overview
  • Therapeutics Development
    • TAR DNA-Binding Protein 43 (TDP-43) - Products under Development by Stage of Development
    • TAR DNA-Binding Protein 43 (TDP-43) - Products under Development by Therapy Area
    • TAR DNA-Binding Protein 43 (TDP-43) - Products under Development by Indication
  • TAR DNA-Binding Protein 43 (TDP-43) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • TAR DNA-Binding Protein 43 (TDP-43) - Products under Development by Companies
  • TAR DNA-Binding Protein 43 (TDP-43) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • TAR DNA-Binding Protein 43 (TDP-43) - Companies Involved in Therapeutics Development
    • Biogen, Inc.
    • ImStar Therapeutics Inc.
    • Primary Peptides, Inc.
    • SK Biopharmaceuticals Co., Ltd.
    • TauRx Therapeutics Ltd.
  • TAR DNA-Binding Protein 43 (TDP-43) - Drug Profiles
    • IMS-088 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NI-205 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit TDP-43 for Amyotrophic Lateral Sclerosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit TANA for ALS, Dementia and Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit TDP-43 for Amyotrophic Lateral Sclerosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Inhibit TDP-43 for Amyotrophic Lateral Sclerosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TRx-0237 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • TAR DNA-Binding Protein 43 (TDP-43) - Dormant Projects
  • TAR DNA-Binding Protein 43 (TDP-43) - Featured News & Press Releases
    • Nov 23, 2015: Aquinnah Pharmaceuticals Receives $680,000 Grant from NINDS To Advance New Therapies for ALS
    • Jan 20, 2015: First Evidence of Potential Efficacy of Tau Aggregation Inhibitor Therapy in Alzheimer's Disease
    • Sep 25, 2014: Proteome Sciences signs $2m contract with Genting TauRx Diagnostic Centre to develop diagnostic panels to detect Alzheimer's disease and monitor treatment efficacy
    • Sep 22, 2014: TauRx Therapeutics Achieves Enrolment Target for Second Phase III Clinical Trial of LMTX in Alzheimer's Disease
    • Jul 15, 2014: TauRx Therapeutics Achieves Enrolment Target in the First of Its Two Phase III Clinical Trials of LMTX in Alzheimer's Disease
    • Jun 18, 2014: University Hospitals Case Medical Center now enrolling patients in clinical trial for Frontotemporal Dementia
    • Mar 27, 2014: TauRx Chairman to present at scientific symposium focused on advances in Alzheimer's treatments
    • Mar 24, 2014: TauRx Therapeutics to present at Social Care Conference in London on 25th
    • Jan 09, 2014: First German Patients Enroll in Phase 3 Clinical Trials of LMTX for Alzheimer's Disease
    • Jan 06, 2014: TauRx Expands Alzheimer's Clinical Trials in the United States
    • Nov 26, 2013: ImStar Therapeutics Selects Lead Drug Candidate for ALS
    • Oct 03, 2013: Professor Claude Wischik, Chairman of TauRx, highlights future consequences of Alzheimer's Disease at annual psychogeriatric conference in Korea
    • Sep 19, 2013: TauRx achieves milestone in global Phase 3 clinical trials of LMTX for Alzheimer's Disease
    • Jun 10, 2013: TauRx Therapeutics And Toronto Memory Program Announce Canadian Launch Of Phase III Clinical Trials Of LMTX For Treatment Of Alzheimer's Disease
    • May 22, 2013: TauRx Therapeutics Enrolls First Patient In Phase III Clinical Trials Of LMTX For Treatment Of Alzheimer's Disease In UK
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Biogen, Inc., H1 2016
  • Pipeline by ImStar Therapeutics Inc., H1 2016
  • Pipeline by Primary Peptides, Inc., H1 2016
  • Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016
  • Pipeline by TauRx Therapeutics Ltd., H1 2016
  • Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top